The main reason for the unfavorable clinical outcome of BCR-ABL1-positive acute lymphoblastic leukemia (ALL) is genetic instability. However, how normal B-cell precursors acquire the genetic changes that lead to transformation has not yet been completely defined. We investigated the expression of the activation-induced cytidine deaminase (AID) and its role in clinical outcome in 61 adult BCR-ABL1-positive ALL patients. AID expression was detected in 36 patients (59%); it correlated with the BCR-ABL1 transcript levels and disappeared after treatment with tyrosine kinase inhibitors. Different AID splice variants were identified: full-length isoform; AIDDE4a, with a 30-bp deletion of exon 4; AIDDE4, with the exon 4 deletion; AIDins3, with the retention of intron 3; AIDDE3-E4 isoform without deaminase activity. AID-FL predominantly showed cytoplasmic localization, as did the AID-DE4a and AID-DE3E4 variants, whereas the C-terminal-truncated AID-DE4 showed a slightly increased nuclear localization pattern. AID expression correlated with a higher number of copy number alterations identified in genome-wide analysis using a single-nucleotide polymorphism array. However, the expression of AID at diagnosis was not associated with a worse prognosis. In conclusion, BCR-ABL1-positive ALL cells aberrantly express different isoforms of AID that may act as mutators outside the immunoglobulin (Ig) gene loci in promoting genetic instability.
Introduction
The BCR-ABL1-positive acute lymphoblastic leukemia (ALL) defines the most frequent and prognostically the most unfavorable subtype of ALL. 1, 2 Recently, 3 in genome-wide analyses of DNA copy number abnormalities and loss of heterozygosity events, using single-nucleotide polymorphism (SNP) microarrays, a high frequency of genetic alterations of regulators of B lymphoid development and cell cycle was reported in different subtypes of B-progenitor ALL, including the BCR-ABL1-positive one. 4, 5 These new findings suggested that additional genomic alterations are frequent events in BCR-ABL1-positive ALL, and are likely central to the pathogenesis and poor outcome of this subtype of leukemia. However, despite the advances made in the last few years in the understanding of the genetics of BCR-ABL1-ALL, how normal B-cell precursor cells acquire the genetic changes that lead to transformation and progression have not been completely defined. Feldhahn et al. 6 proposed that the aberrant expression of the B cell-specific mutator enzyme activation-induced cytidine deaminase (AID) in BCR-ABL1-transformed ALL cells may act as a mutator not only within but also outside the Ig gene loci.
The AID was identified by the Honjo laboratory in 1999 7, 8 in a search for cDNAs that were specifically expressed in B cells on class-switch recombination (CSR) activation. Soon after that, the generation of AID-deficient mice proved that AID is required not only for CSR but also for antibody somatic hypermutation (SHM) in germinal center (GC) B cells, 9 and that the deficiency of AID in humans is associated with an immune deficiency called Hyper-IgM type 2 syndrome. 10 Today, there is compelling genetic and biochemical evidence showing that AID initiates SHM and CSR by deaminating cytosines to uracil. The resulting uracil-guanidine mismatches are repaired by error-prone DNA repair mechanisms leading to the introduction of mutations. 11, 12 Deregulated expression of AID has been reported in GC-derived lymphomas and in leukemias or lymphomas originated from B cells at other stages of differentiation. 13, 14 AID has also been shown to trigger mutations and chromosomal instability more broadly than previously thought, with numerous tumor-related genes, including Myc, Pim1, Pax5, H2afx, Ocab, Rhoh and Ebf1, now shown as AID targets in normal B cells. The ultimate distribution of mutations is determined by a balance between high-fidelity and error-prone DNA repair. 15 Besides its aberrant expression, AID is also alternatively spliced into five mRNA variants in addition to the full-length (FL) form in B-cell malignancies including a subset of B-cell chronic lymphocytic leukemia 16 and various types of B-cell lymphomas. 14, 17 Recently, different AID splice variants were also found in normal GC human B cells and blood memory B cells, and have been shown to display different activities ranging from inactivation of CSR to inactivation or heightened SHM activity. 18 As few data are available about AID expression and pre-B ALL, we analyzed AID expression in 61 adult de novo BCR-ABL1-positive ALL patients. AID expression was found in 59% of Ph þ ALL and different AID splice variants were identified. To further investigate whether AID expression would be correlated with increased DNA single-strand breaks, we performed a genomewide analysis by 250K NspI and SNP 6.0 arrays (Affymetrix Inc., Santa Clara, CA, USA) and found that ALL patients with expression of wild-type AID have a higher number of copy number alterations (CNAs) compared with patients not expressing AID. Finally, we searched whether recurring CNAs were identified in genes with an established role in leukemogenesis focusing on PAX5, CDKN2A, CDKN2B, BTG1 and EBF1.
Patients and methods

Patients
After obtaining informed consent, we collected peripheral blood or bone marrow in Vacutainer tubes with EDTA anticoagulated from 61 patients with BCR-ABL1-positive adult ALL patients. They had a median age of 56 years (range: 18-76) and showed a median blast percentage at diagnosis of 90% (range: 18-99). Diagnosis of all ALL cases was made on the basis of morphological, biochemical and immunological features of the leukemic cells. In addition, the human BCR-ABL1 leukemia cell lines SD1 and BV173 were also included in the analysis. Cell lines were obtained from DMSZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Braunschweig, Germany) and maintained in culture following the DMSZ recommendations.
AID transcript analysis
Mononuclear cells were separated by Ficoll-Hypaque density gradient centrifugation, and after RNA extraction, 1 mg was used for cDNA synthesis as previously described. 19 To set up a screening for AID transcript variants, cDNA was amplified with a pair of oligonucleotides whose forward primer conjugated with a fluorescent dye (fluorescein, excitation occurs at 494 nm and emission at 521 nm) at its 5 0 . Primer sequences were: F1: 5 0 -CTATGGACAGCCTCTTGATGAACC-3 0 and R1: 5 0 -CCCAAA GTACGAAATGCGTCTCG-3 0 . PCR was performed using 1 U of Fast Start (Roche Diagnostics, Mannheim, Germany) DNA polymerase and a final concentration of 1.5 mM MgCl2, on a BIOMETRA Tpersonal thermal cycler (Biometra biomedizinische Analytik GmbH, Goettingen, Germany) set for an initial denaturation at 95 1C for 5 min, for 40-45 cycles with denaturation at 95 1C for 30 s, annealing at 62 1C for 30 s, extension at 72 1C for 45 s, and a final cycle at 72 1C for 10 min and at 60 1C for 45 min to stabilize the fluorescence. In total, 1 ml of each amplicon was added to 9 ml of formaldehyde (Sigma-Aldrich, St Louis, MO, USA) containing 0.2 ml of GeneScan 500 (À250) LIZ size standard (Applied Biosystems, Foster City, CA, USA) and loaded on the ABI Prism 3730 DNA Analyzer for automated capillary gel electrophoresis, and the results were plotted with the AbiPrism GeneMapper v3.5 software (Applied Biosystems). The GeneMapper electrophoretograms displayed information about transcript length, peak height and peak area.
Cloning and sequencing analyses
Nucleotide sequences of all the observed amplicons were validated by repeating the PCRs with 5 0 -unmodified primers and cloning the products into pcR2.1-TOPO vectors using the TOPO TA cloning kit and related protocol (Invitrogen, San Diego, CA, USA). TOP10F' (controllare) strain E. coli cells (Invitrogen) were used as a host for transformation, and colonies containing the recombinant plasmids were screened by PCR with the primer pair for the appropriate amplicon and at the same conditions described previously. PCR products were purified with the QIAquick PCR purification kit (Qiagen, Hilden, Germany) and directly sequenced by using the ABI PRISM 3730 automated DNA sequencer (Applied Biosystem) and a Big Dye Terminator DNA sequencing kit (Applied Biosystem).
Monitoring of BCR-ABL transcript levels BCR-ABL1 mRNA transcript levels were detected at diagnosis and during follow-up using a standardized real-time quantitative PCR method that was established within the framework of the EU Concerted Action. 20 Real-time quantitative PCR was performed on an ABI PRISM 7900 Sequence Detector (Perkin Elmer, Foster City, CA, USA). The quantification principles and procedure using the TaqMan probe (Applied Biosystems) have been previously described. 21 All real-time RT-PCR experiments were performed in duplicate.
Western blotting
Cells were lysed with sample buffer (2% SDS in 125 mM Tris-HCL, pH 6.8). Cell lysates were subjected to SDS-PAGE (polyacrylamide gel electrophoresis) on 12% gels and then transferred to nitrocellulose membranes (Amersham Biosciences, Cologno Monzese, MI, Italy). The blots were incubated for 60 min in the Odyssey blocking buffer before incubation overnight (4 1C) with the polyclonal anti-AID antibody (L7E7 Mouse mAb, Cell Signaling Technology, Danvers, MA, USA). Blotted proteins were detected and quantified using the Odyssey infrared imaging system LI-COR (LI-COR Biosciences, Bad Homburg, Germany).
Subcellular localization studies using confocal laser scanning microscopy
The subcellular localization of AID proteins was examined by immunofluorescence and confocal laser scanning microscopy as previously described. 22 
SNP microarray analysis
Genomic DNA was extracted using the DNA Blood Mini Kit (Qiagen, Valencia, CA, USA) from mononuclear cells isolated from peripheral blood or bone marrow aspirate samples by Ficoll gradient centrifugation. DNA was quantified using the Nanodrop Spectrophotometer (Thermo Scientific, Wilmington, DE, USA) and quality was assessed by using the Nanodrop and by agarose gel electrophoresis.
Samples were genotyped with GeneChip Human Mapping 250K NspI and Genome-Wide Human SNP 6.0 array microarrays (Affymetrix Inc.) and according to the manufacturer's instructions. Array image data were analyzed using the Affymetrix GCOS v. 1.4 operating software (Affymetrix Inc.) and Genotyping Console v. 3.0 (Affymetrix Inc.) to derive .cel data files, which were also exported to the Partek Genomic Suite (Partek Inc., Saint Louis, MO, USA) for further data visualization and analysis. All aberrations were calculated with respect to a set of 270 Hapmap normal individuals and a set of samples obtained from acute leukemia cases in remission to reduce the noise of raw copy number data. When available, to exclude inherited copy number variants, a comparison with paired constitutional DNA and with paired remission DNA was performed. Copy number aberrations were also analyzed and eventually confirmed using Genotyping Console 3.0 (Affymetrix Inc.).
Statistical analysis
The primary study end points were achievement of complete remission (CR), duration of first CR (in terms of disease-free survival (DFS) and of cumulative incidence of relapse), and overall survival. Median follow-up time was estimated by reversing the codes for the censoring indicator in a KaplanMeier analysis. 23 Differences in the distributions of prognostic factors in subgroups were analyzed by w 2 or Fisher's exact test, and by the Kruskal-Wallis test. Survival was defined as the time from diagnosis to death or date of last follow-up. DFS and relapse incidence were calculated from the time of achieving CR to relapse, death or date of last follow-up. The probabilities of overall survival and DFS were estimated using the KaplanMeier method, 23 and the probability of cumulative incidence 24 of relapse was estimated using the appropriate non-parametric method, considering death in CR as a competing risk. The logrank test was used to compare the treatment effect and risk factor categories, and confidence intervals were estimated (95% CIs) using the Simon and Lee method. 25 Cox proportional hazard regression models were used to examine and check for treatment results and the risk factors affecting the time to the event.
All tests were two-sided, accepting Pp0.05 as indicating a statistically significant difference. All analyses were performed using the SAS software (SAS Institute, Cary, NC, USA).
Results
Aberrant AID expression in Ph þ ALL depends on BCR-ABL1 kinase activity
Studying AID mRNA and protein expression in 61 cases of Ph þ ALL, AID expression was detected in 36 of 61 (59%) patients. To investigate whether the AID expression was correlated to the BCR-ABL1 kinase activity, we simultaneously monitored in vivo the BCR-ABL1 mRNA levels by quantitative PCR and the AID mRNA and protein expression before and after treatment with tyrosine kinase inhibitor (TKI) in eight diagnosis-remissionrelapse matched samples. One patient was treated with imatinib and the remaining patients with dasatinib. We found that the AID expression correlated with the BCR-ABL1 mRNA levels: patients were AID þ at diagnosis when the median ratio percentage of BCR-ABL1/ABL was 30.86 (range: 1.30-85.90), but they became negative during treatment with tyrosine kinase inhibitors at the time of remission when they reached undetectable levels of BCR-ABL1 mRNA (median ratio percentage of BCR-ABL1/ABL is less than 0.0001). As soon as the BCR-ABL1 transcript levels increased because of the loss of response, expression of AID was once again detected (Figures 1a and b) .
Different AID splice variants are expressed
The human AID protein possesses multiple functional domains important for the physiological functions of AID in CSR and SHM, and/or for its potential pathological role in tumorigenesis ( Figure 2 ). Different isoforms of AID were expressed following alternative splicing in BCR-ABL1-positive cells. In 13 of 61 (21%) Ph þ ALL patients, the FL isoform of 592 bp (GeneBank accession number NM_020661) was identified. In 19 of 61 (31%) Ph þ ALL patients, we identified the coexpression of the wild-type isoform and minor bands of various sizes comprising differing domains. In particular, we found a band of 562 bp corresponding to an isoform with a 30-bp deletion of exon 4 (AID-DE4a) and a band of 476 bp corresponding to an isoform characterized by the deletion of the entire exon 4 (AID-DE4), which led to a C-terminal truncation because of a frameshift. In two patients, we also found a band of 884 bp corresponding to AIDins3, which is characterized by the retention of intron 3. This variant maintains the cytidine domain responsible for the activity of cytidine deamination but lacks the CSR domain because of a frameshift. Overall, 4 of 61 Ph þ ALL patients (7%) expressed the AID DE3-E4 isoform without deaminase activity (deletion of exons 2 and 3) but retaining intact the CSR domain (Figures 2 and 3) . Thus, the splicing variants would display an assortment of functional defects when compared with the FL counterpart, and because of this, may constitute a novel mechanism of regulation of CSR and SHM.
AID splice variants have different cellular localization
Next, we asked whether the different splicing variants could have altered cellular localization as a result of splicing-induced alterations in the nuclear export signal (NES) in its Cterminus. 26, 27 Physiologically, AID is a nucleocytoplasmic shuttling protein with a bipartite nuclear localization signal and a NES in its N and C termini, respectively. The amount of AID in the nucleus at the steady state must be tightly controlled to maintain a minimal level, because excessive amounts of nuclear AID may induce unregulated SHM not only in the Ig genes but also in the non-Ig genes. 26 As shown in Figure 4 , we found that AID-FL showed predominant cytoplasmic localization (panel a), as did the AID-DE4a and AID-DE3E4 variants (panels b and c). This observation was because of the fact that internal in-frame deletions by splicing do not affect either the nuclear localization signal or NES domains, and this is in agreement with previous AID in BCR-ABL1-positive ALL I Iacobucci et al papers indicating that predominant cytoplasmic localization of AID is normal because B cells cannot tolerate AID being predominantly localized in the nucleus. 26, 28 However, the C-terminal-truncated AID-DE4 showed a slightly increased nuclear localization (panel d) (P ¼ 0.0001).
AID promotes genetic instability
Activation-induced cytidine deaminase is an enzyme that physiologically hypermutates Ig genes introducing DNA single-strand breaks. In the absence of effective DNA repair, such DNA single-strand breaks may lead to genetic lesions, such as deletions or chromosomal translocations. To investigate whether AID expression in BCR-ABL1-positive ALL was associated with an increased number of genomic lesions, we performed a genome-wide analysis by SNP arrays (Affymetrix Inc., 250K NspI and SNP 6.0). Interestingly, AID-positive leukemias had a higher number of alterations compared with AID-negative leukemias: cases with AID-positive BCR-ABL1 leukemia had a median CNA of 14 (range: 6-50) compared with 5 CNAs in AID-negative leukemias (range: 2-8, P ¼ 0.02). Genes that were recurrently subject to CNAs were compared for their relative frequency of deletion/amplification events in AIDpositive and -negative leukemias. Recurring copy number abnormalities were identified in genes with an established role in leukemogenesis, such as CDKN2A, CDKN2B, GADD45, PAX5, BTG1, EBF1 and MDS1. In particular, we found that the pattern of AID expression correlated with a high frequency of DNA single-strand breaks within the tumor suppressor genes CDKN2A (Arf) and CDKN2B (INK4B), located at 9p21 (P ¼ 0.03) ( Table 1 ). These findings are in agreement with those reported by Feldhahn et al., 6 showing that AID expression is required to induce DNA single-strand breaks in the CDKN2B gene.
Moreover, our results suggest that the increased expression and aberrant activity of AID not only leads to additional genetic lesions but is also associated with poor outcome. To test this possibility, we investigated a potential correlation between outcome and AID expression in Ph þ ALL cells.
AID expression is not correlated with a poor outcome Patient's characteristics. Of 61 BCR-ABL1-positive ALL patients, 56 (67%) could be evaluated for correlation with clinical outcome, and for 5 patients the clinical data were not available, as they were lost at follow-up. The characteristics of the patients are shown in Table 2 . The median follow-up was 14.8 months (range: 0.4-148.1 months). Initial white blood cells counts ranged between 1.400 and 146.000 per pl (median, 28.100 per pl). No patient had symptomatic central nervous system disease at diagnosis. All cases were evaluable for central review. A total of 46 patients (82%) were enrolled in the GIMEMA clinical trials (3 patients in the GIMEMA LAL 0201-B protocol, 1 patient in LAL2000 and 42 patients in the LAL1205 protocol), whereas 10 patients (18%) were enrolled in institutional protocols. The therapy schemes related to the individual protocols have been described earlier. 22, [29] [30] [31] [32] AID expression and prognosis. Among these patients, AID expression (wild-type isoforms and splicing-derived isoforms containing the cytidine deaminase domain) was detected in 28 cases (50%). The remaining patients (50%) were negative (n ¼ 24) or expressed AID isoforms lacking the cytidine deaminase domain (n ¼ 4). All patients started induction therapy and were consequently evaluable for complete CHR (by intention to treat or ITT). If a patient had lost the final evaluation of the treatment, he/she was evaluated at the last visit available (last observation carry forward or LOCF).
All patients (100%) who were enrolled in protocol LAL1205 (Dasatinib frontline) and LAL-0201-B (imatinib and steroids as frontline therapy for elderly patients) obtained a complete hematological response. Therefore, patients evaluable for a correlation between CHR and AID expression were 10 (18%), but among these only 1 had a loss of response, and therefore the association with response was not reachable.
The median time of cumulative incidence of relapse of the entire population was 17 months, but we did not find a significant difference between patients who expressed AID and patients who were negative (P ¼ 0.5636) (Supplementary Figure  1SA) . AID expression was also not significantly correlated with overall survival (P ¼ 0.8034) and DFS (P ¼ 0.5178) (Supplementary Table 1S and Supplementary Figure 1SB-C) . The survival did not also change when different AID variants were correlated with DFS (Supplementary Table 2S ). In the Supplementary Table  3S , results from the multivariate analysis were reported. 
Discussion
Physiological AID is required for CSR and SHM in B cells of GC origin by targeting Ig gene loci. However, AID can also target many other endogenous gene loci in normal GC B cells, and the frequency of AID-mediated mutagenesis of non-Ig genes is greater in malignant B cells. 13, 33 A recent work 15 showed that AID has the potential to trigger mutations and chromosomal instability more broadly than previously thought, with numerous tumor-related genes, including Myc, Pim1, Pax5, H2afx, Ocab, Rhoh and Ebf. In many of these genes, there was a clear correspondence between regions targeted by AID and sites of chromosomal deletions and translocations in human B-cell lymphomas. 34 The ultimate distribution of mutations is determined by a balance between high-fidelity and error-prone DNA repair. Besides its aberrant expression, AID is also alternatively spliced into four mRNA variants in addition to the FL form in B-cell malignancies, 16 including a subset of B-cell chronic lymphocytic leukemia and various types of B-cell lymphomas. 14, 17 There is also limited evidence that AID alternative splicing may occur in normal B lineage cells. 18 As alternative splicing generates isoforms with different exon organization, it significantly impairs AID functional activity.
Here, we reported for the first time in BCR-ABL1-positive ALL the expression of different AID isoforms derived from alternative splicing maintaining (FL, AID-DE4a, AID-DE4, AIDins3) and not maintaining (AID DE3-E4) the cytidine deaminase domain. Among 61 de novo adult BCR-ABL1-positive ALL patients, AID mRNA and protein were detected in 36 (59%); their expression correlated with BCR-ABL1 transcript levels and disappeared after treatment with tyrosine kinase inhibitors at the time of remission. Different isoforms of AID were identified: 13 We performed a quantification of the signal intensities and the increased nuclear localization was statistically significant just in AID-deltaE4 (d) (P ¼ 0.0001), whereas the variation that occurred in AID-DE4a and AID-DE3E4 was not significant (P ¼ 0.8 and P ¼ 0.9, respectively) with respect to the AID wild type. 18 showed that the DE4a and DE4 variants express a higher level of SHM activity than FL AID, as the DE4 variant completely lacks the CSR domain, and the 10-amino acid in-frame deletion in DE4a leads to the structural repositioning of the C-terminal domain that may likewise alleviate the inhibitory influence of an intact CSR domain on SHM. 35 AID has a nuclear localization signal and a NES, and can thereby dynamically shuttle between the nucleus and cytoplasm. The cellular localization of AID seems to be essential to its function, and excessive amounts of nuclear AID have been shown to induce unregulated SHM not only in the Ig genes but also in the non-Ig genes. 26 As alternative splicing may induce alterations in the NES in its C-terminus, we found that AID-FL showed predominant cytoplasmic localization, as did the AID-DE4a and AID-DE3E4 variants, whereas the C-terminal-truncated AID-DE4 showed a slightly increased nuclear localization pattern.
To investigate whether AID introduces DNA single-strand breaks, we next performed a genome-wide analysis by SNP array (Human Mapping NspI 250K and Genome-Wide SNP6.0, Affymetrix Inc.). Patients who expressed wild-type AID had a higher number of alterations compared with AID-negative patients (median CNA of 14 versus 4, respectively, Po0.02).
In particular, we found that the pattern of AID expression correlated with a high frequency of DNA single-strand breaks within the tumor suppressor genes CDKN2A (ARF) and CDKN2B (INK4B), located at 9p21 (P ¼ 0.03). Mouse modeling of Ph þ ALL revealed that Arf inactivation attenuates responsiveness to targeted BCR-ABL kinase inhibitors, enhances the maintenance of leukemia-initiating cells within the hematopoietic microenvironment and facilitates the emergence of malignant clones that harbor drug-resistant BCR-ABL kinase mutations. 36 However, our failure to correlate the AID expression with clinical outcome in vivo suggests that although BCR-ABL1-dependent AID-driven genomic instability may contribute to the development/malignancy of Ph-positive ALL (where numerous genetic aberrations are detectable at diagnosis), it does not contribute to the relapse. As TKIs abrogate AID expression (Figure 1a) and Ph-positive ALLs usually display relatively short-term response to the inhibitors, it is plausible that relapses originate from already existing pre-TKI malignant clones. In this scenario, AID contributes to the induction of Ph-positive ALL, but not to its progression. Furthermore, the failure to correlate AID expression with clinical outcome could be attributed to the heterogeneity of treatments and the short follow-up. It is noteworthy that the majority of patients were treated with dasatinib as frontline therapy, which induced a complete hematological remission in all patients precluding us from performing any correlative analysis. Mouse models are currently under investigation by our group to show whether the expression of AID is responsible in vivo for disease progression.
In conclusion, our findings showed that BCR-ABL1-positive ALL cells aberrantly express different isoforms of AID that can act as a mutator outside the Ig gene loci in promoting genetic instability in leukemia cells.
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